2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
48
Neoplasm Metastasis
11
Hereditary Sensory and Autonomic Neuropathies
7
Squamous Cell Carcinoma of Head and Neck
5
Recurrence
5
Ovarian Neoplasms
5
Neoplasms
5
Triple Negative Breast Neoplasms
3
Multiple Endocrine Neoplasia Type 1
3
Lymphangioma
3
Hyperglycemia
3
Head and Neck Neoplasms
3
Pancreatic Neoplasms
2
Melanoma
2
Lymphatic Abnormalities
2
Lymphangioma, Cystic
2
Head and Neck Squamous Cell Cancer
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Advanced Breast Cancer
2
Vascular Malformations
1
Uveal Melanoma
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Diseases, Vascular
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pre-menopausal Breast Cancer
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Surveys and Questionnaires
16
Bevacizumab
14
Cisplatin
12
Blood Specimen Collection
11
Drug Therapy
10
Standard of Care
9
Nivolumab
9
Gemcitabine
9
Cetuximab
7
pembrolizumab
6
Specimen Handling
6
S 1 (combination)
6
Endoscopic Mucosal Resection
6
Cyclophosphamide
6
atezolizumab
5
Sunitinib
5
Radiotherapy
5
Folfox protocol
5
Educational Status
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Radiosurgery
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Alpelisib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled